Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


pSivida drug delivery data

This article was originally published in The Gray Sheet

Executive Summary

Preliminary data from a four-patient safety trial suggest that pSivida's BrachySil nanotechnology liver cancer treatment device achieves 80% tumor regression by volume, with no product-related adverse events. A dose-profiling study will begin shortly, followed by a multicenter pivotal trial in Europe and the U.S. The Australian firm aims to license the drug-delivery device to a top pharma firm during 2005 (1"The Gray Sheet" Feb. 14, 2005, p. 28)...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts